152 related articles for article (PubMed ID: 36055806)
1. [Immunotherapy in advanced gastric cancer].
Zaanan A
Bull Cancer; 2022 Oct; 109(10):1066-1072. PubMed ID: 36055806
[TBL] [Abstract][Full Text] [Related]
2. Recent progress and current challenges of immunotherapy in advanced/metastatic esophagogastric adenocarcinoma.
Moehler M; Högner A; Wagner AD; Obermannova R; Alsina M; Thuss-Patience P; van Laarhoven H; Smyth E
Eur J Cancer; 2022 Nov; 176():13-29. PubMed ID: 36183651
[TBL] [Abstract][Full Text] [Related]
3. Immunotherapy in Gastric Cancer.
Högner A; Moehler M
Curr Oncol; 2022 Mar; 29(3):1559-1574. PubMed ID: 35323331
[TBL] [Abstract][Full Text] [Related]
4. [Localized MSI/dMMR gastric cancer patients, perioperative immunotherapy instead of chemotherapy: The GERCOR NEONIPIGA phase II study is opened to recruitment].
Cohen R; Pudlarz T; Garcia-Larnicol ML; Vernerey D; Dray X; Clavel L; Jary M; Piessen G; Zaanan A; Aparicio T; Louvet C; Tournigand C; Chibaudel B; Tougeron D; Guimbaud R; Benouna J; Adenis A; Sokol H; Borg C; Duval A; Svrcek M; André T
Bull Cancer; 2020 Apr; 107(4):438-446. PubMed ID: 32057467
[TBL] [Abstract][Full Text] [Related]
5. Clinical Significance of Molecular Subtypes in Western Advanced Gastric Cancer: A Real-World Multicenter Experience.
Salati M; Ghidini M; Paccagnella M; Reggiani Bonetti L; Bocconi A; Spallanzani A; Gelsomino F; Barbin F; Garrone O; Daniele B; Dominici M; Facciorusso A; Petrillo A
Int J Mol Sci; 2023 Jan; 24(1):. PubMed ID: 36614254
[TBL] [Abstract][Full Text] [Related]
6. Current status of immunotherapy for advanced gastric cancer.
Kawazoe A; Shitara K; Boku N; Yoshikawa T; Terashima M
Jpn J Clin Oncol; 2021 Jan; 51(1):20-27. PubMed ID: 33241322
[TBL] [Abstract][Full Text] [Related]
7. Immunotherapy in esophagogastric cancer.
Ilson DH
Clin Adv Hematol Oncol; 2021 Oct; 19(10):639-647. PubMed ID: 34637430
[TBL] [Abstract][Full Text] [Related]
8. Low Programmed Death-Ligand 1-Expressing Subgroup Outcomes of First-Line Immune Checkpoint Inhibitors in Gastric or Esophageal Adenocarcinoma.
Zhao JJ; Yap DWT; Chan YH; Tan BKJ; Teo CB; Syn NL; Smyth EC; Soon YY; Sundar R
J Clin Oncol; 2022 Feb; 40(4):392-402. PubMed ID: 34860570
[TBL] [Abstract][Full Text] [Related]
9. Nivolumab for the treatment of colorectal cancer.
Smith KM; Desai J
Expert Rev Anticancer Ther; 2018 Jul; 18(7):611-618. PubMed ID: 29792730
[TBL] [Abstract][Full Text] [Related]
10. Immunotherapy-Based Neoadjuvant Treatment of Advanced Microsatellite Instability-High Gastric Cancer: A Case Series.
Liu L; Woo Y; D'Apuzzo M; Melstrom L; Raoof M; Liang Y; Afkhami M; Hamilton SR; Chao J
J Natl Compr Canc Netw; 2022 Aug; 20(8):857-865. PubMed ID: 35948034
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy for gastric cancer: a 2021 update.
Kole C; Charalampakis N; Tsakatikas S; Kouris NI; Papaxoinis G; Karamouzis MV; Koumarianou A; Schizas D
Immunotherapy; 2022 Jan; 14(1):41-64. PubMed ID: 34784774
[TBL] [Abstract][Full Text] [Related]
12. Checkpoint inhibitors in metastatic gastric and GEJ cancer: a multi-institutional retrospective analysis of real-world data in a Western cohort.
Schlintl V; Huemer F; Rinnerthaler G; Melchardt T; Winder T; Reimann P; Riedl J; Amann A; Eisterer W; Romeder F; Piringer G; Ilhan-Mutlu A; Wöll E; Greil R; Weiss L
BMC Cancer; 2022 Jan; 22(1):51. PubMed ID: 35012477
[TBL] [Abstract][Full Text] [Related]
13. Towards exertion of immunotherapeutics in the treatment of colorectal cancer; adverse sides, challenges, and future directions.
Pan W; Zhao J; Zhang S; Chen X; Liang W; Li Q
Int Immunopharmacol; 2021 Dec; 101(Pt B):108337. PubMed ID: 34775366
[TBL] [Abstract][Full Text] [Related]
14. Immunotherapy in Gastroesophageal Cancers: Current Evidence and Ongoing Trials.
Huynh J; Patel K; Gong J; Cho M; Malla M; Parikh A; Klempner S
Curr Treat Options Oncol; 2021 Sep; 22(11):100. PubMed ID: 34524553
[TBL] [Abstract][Full Text] [Related]
15. Prognostic factors to predict the survival in patients with advanced gastric cancer who receive later-line nivolumab monotherapy-The Asahikawa Gastric Cancer Cohort Study (AGCC).
Tanaka K; Tanabe H; Sato H; Ishikawa C; Goto M; Yanagida N; Akabane H; Yokohama S; Hasegawa K; Kitano Y; Sugiyama Y; Uehara K; Kobayashi Y; Murakami Y; Kunogi T; Sasaki T; Takahashi K; Ando K; Ueno N; Kashima S; Moriichi K; Sato K; Yuzawa S; Tanino M; Taruiishi M; Sumi Y; Mizukami Y; Fujiya M; Okumura T
Cancer Med; 2022 Jan; 11(2):406-416. PubMed ID: 34845844
[TBL] [Abstract][Full Text] [Related]
16. Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer.
Kadono T; Yamamoto S; Kato K
Jpn J Clin Oncol; 2022 Oct; 52(10):1089-1096. PubMed ID: 36047845
[TBL] [Abstract][Full Text] [Related]
17. Durable Complete Radiological Response to Nivolumab in Two Heavily Pretreated Western Elderly Patients With Metastatic Gastric Cancer: A Case Report.
Tirino G; Petrillo A; Pompella L; Pappalardo A; Laterza MM; Panarese I; Sabetta R; Franco R; Galizia G; Ciardiello F; De Vita F
Front Oncol; 2020; 10():130. PubMed ID: 32128313
[No Abstract] [Full Text] [Related]
18. Targeting the PD-1 pathway: a new hope for gastrointestinal cancers.
Bilgin B; Sendur MA; Bülent Akıncı M; Şener Dede D; Yalçın B
Curr Med Res Opin; 2017 Apr; 33(4):749-759. PubMed ID: 28055269
[TBL] [Abstract][Full Text] [Related]
19. Remnant gastric cancer: a neglected group with high potential for immunotherapy.
Ramos MFKP; Pereira MA; de Castria TB; Ribeiro RRE; Cardili L; de Mello ES; Zilberstein B; Ribeiro-Júnior U; Cecconello I
J Cancer Res Clin Oncol; 2020 Dec; 146(12):3373-3383. PubMed ID: 32671505
[TBL] [Abstract][Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
